
PE-22-28
PE-22-28 (Spadin analog)
Potential Benefits
- Animal studies suggest antidepressant-like effects through TREK-1 channel blockade
- Preclinical data indicates rapid onset of action (days rather than weeks) compared to traditional antidepressants
- Research suggests potential for neurogenesis in the hippocampus
- May improve stress resilience in animal models
- Does not appear to cause the side effects associated with traditional SSRI medications in animal studies
Recommended Starting Dose
Not established for humans; animal studies use doses that are not directly translatable
Based on published research protocols. Not a prescription.
Dosing Protocol
No established human dosing protocol. This peptide is referenced in animal research only. Anyone considering this compound should understand that no human safety or efficacy data exists.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
Animal studies suggest effects within 4-7 days. No human timeline data exists.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- No published human safety data
- All current data is from animal models
- Unknown interactions with existing psychiatric medications
- Long-term effects are completely uncharacterized
- Quality and purity concerns with research-grade compounds
More in Cognitive

Selank
Selank
Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is derived from the naturally occurring immunomodulatory peptide tuftsin with an added Pro-Gly-Pro sequence for stability. It is approved in Russia as an anxiolytic and nootropic nasal spray.

Semax
Semax
Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4-10) with an added Pro-Gly-Pro C-terminal tripeptide for metabolic stability. Developed in Russia, it is approved there for conditions including stroke recovery, cognitive disorders, and peptic ulcers. It is administered intranasally.

Dihexa
Dihexa
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic peptide derived from angiotensin IV. Developed at Washington State University by Dr. Joseph Harding, it was found to be up to 10 million times more potent than BDNF at promoting hepatocyte growth factor (HGF) signaling. Research has focused on its potential to drive synaptogenesis and cognitive enhancement.
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.